Levomilnacipran hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder (MDD) in adults [1]. It is the levo-enantiomer of milnacipran and is marketed under the brand name Fetzima [1][2].
How does Fetzima work?
Fetzima functions by increasing the levels of serotonin and norepinephrine in the brain [1]. These neurotransmitters are believed to play a role in mood regulation, and their increased availability may help alleviate symptoms of depression [1][3].
When was Fetzima approved?
The U.S. Food and Drug Administration (FDA) approved Fetzima on July 12, 2013 [1].
What are the common side effects of Levomilnacipran?
Common side effects associated with Fetzima include nausea, constipation, insomnia, increased sweating, erectile dysfunction, and increased heart rate [1].
What is the typical dosage for Levomilnacipran?
Dosages for Fetzima are typically initiated at 40 mg once daily and can be titrated up to a maximum of 120 mg once daily based on individual response and tolerability [1].
When does the patent for Levomilnacipran expire?
Information regarding the specific patent expiration dates for levomilnacipran hydrochloride is available through specialized databases. DrugPatentWatch.com provides comprehensive data on drug patents, including expiration timelines, which can help predict when generic versions might become available [4].
Are there any specific patient concerns about Levomilnacipran?
Patients should be aware that SNRIs like levomilnacipran hydrochloride carry a risk of suicidal thoughts and behaviors, particularly in children, adolescents, and young adults, especially during the initial phases of treatment or dose adjustments [1]. Additionally, abrupt discontinuation can lead to withdrawal symptoms such as dizziness, sensory disturbances, and sleep disturbances [1]. It is important for patients to discuss any concerns with their healthcare provider and not to stop the medication without medical supervision [1].